Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.34 |
| ▸ | DBH | P09172 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15342383 | 0.86 | PDGFRB (0.35) | CACNA1HPDGFRBPDGFRATUBB1DBH | |
| SCHEMBL31063342 | 0.86 | CA2 (0.41) | GABRA1GABRB2CACNA1HMAPTCA1 | |
| SCHEMBL31063374 | 0.84 | GABRA1 (0.34) | GABRA1GABRB2CACNA1HTUBB1AKR1C3 | |
| SCHEMBL19154839 | 0.82 | POLB (0.37) | GABRA1GABRB2POLBHTR1DALOX5AP | |
| SCHEMBL21849062 | 0.79 | RARG (0.36) | CACNA1HPDGFRBPDGFRATUBB1DBH | |
| SCHEMBL12390575 | 0.76 | PDE5A (0.37) | GABRA1GABRB2POLBHTR1DTUBB1 | |
| SCHEMBL13208392 | 0.76 | TUBB1 (0.38) | GABRA1GABRB2CACNA1HPOLBHTR1D | |
| SCHEMBL19154832 | 0.76 | GABRA1 (0.33) | GABRA1GABRB2POLBHTR1DACHE | |
| SCHEMBL7848211 | 0.75 | POLB (0.48) | GABRA1GABRB2POLBHTR1DTP53 | |
| SCHEMBL19803239 | 0.74 | TUBB1 (0.35) | GABRA1GABRB2POLBHTR1DTUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-11214541-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2022-01-04 | — | — | US | disclosed |
| US-20210323916-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2021-10-21 | — | — | US | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-10570090-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2020-02-25 | — | — | US | disclosed |
| US-20180079720-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-03-22 | — | — | US | disclosed |
| US-20180079720-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-03-22 | — | — | US | disclosed |
| US-9714221-B1 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC. | 2016-01-21 | — | — | US | disclosed |
| US-9029384-B2 | Phosphatidylinositol 3-kinase inhibitors | Gilead Calistoga, LLC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110207751-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2011-08-25 | — | — | US | disclosed |
| US-7932284-B2 | Indole sulfonamide modulators of progesterone receptors | ELI LILLY AND COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570090-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | CYP19A1, ESR1, GPER1 | GABRA1 739/4885GABRB2 993/4885CACNA1H 4367/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GABRA1 859/4885GABRB2 430/4885CACNA1H 4236/4885 |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | GABRA1 3544/4885GABRB2 3423/4885CACNA1H 4292/4885 |
| US-11214541-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | CYP19A1, ESR1, GPER1 | GABRA1 739/4885GABRB2 993/4885CACNA1H 4367/4885 |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | GABRA1 3096/4885GABRB2 3307/4885CACNA1H 3666/4885 |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | PGR, NPSR1, PRLHR | GABRA1 444/4885GABRB2 470/4885CACNA1H 2073/4885 |
| US-20210323916-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, ESR1, ESR2 | GABRA1 930/4885GABRB2 1307/4885CACNA1H 4394/4885 |
| US-20110207751-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | MKI67, CCNC, NUDC | GABRA1 4063/4885GABRB2 3543/4885CACNA1H 4736/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GABRA1 859/4885GABRB2 430/4885CACNA1H 4236/4885 |
| US-20180079720-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, ESR1, ESR2 | GABRA1 930/4885GABRB2 1307/4885CACNA1H 4394/4885 |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | GABRA1 3096/4885GABRB2 3307/4885CACNA1H 3666/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | GABRA1 405/4885GABRB2 316/4885CACNA1H 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.